Mind Medicine Mindmed Inc (MNMD) Stock Price, Quote & News

Company Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is head...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 220 6633

Website: www.mindmed.co

Address:

One World Trade Center, Suite 8500, New York, United States

a_rational_investor Jan. 14 at 2:59 PM

$MNMD can’t wait for tomorrows ticker change. I know it doesn’t matter much but it’s almost as if we’re starting a new era and gearing up for a great 2026 with some great phase threes

1 · Reply

Rocketzz Jan. 14 at 3:37 AM

$MNMD phase 3 results are going to drop the morning after Goral’s mom kicks him off her cell phone plan and changes the WiFi password. Kids gonna get rekt

1 · Reply

CANADX Jan. 14 at 12:20 AM

$MNMD I just keep holding. It’s been 5 years and all I know is mushrooms are good and $NUMI.X my other mushroom play stopped trading a long time ago.

1 · Reply

lindakooy Jan. 13 at 10:31 PM

$MNMD interesting company.

1 · Reply

Rocketzz Jan. 13 at 9:45 PM

$MNMD larger market cap than $ATAI

2 · Reply

Rocketzz Jan. 13 at 9:34 PM

$MNMD

0 · Reply

flamingojack Jan. 13 at 9:21 PM

$MNMD

0 · Reply

Alien1980 Jan. 13 at 8:57 PM

$MNMD was all buys above 14.72. Another quick scalp back to 15.1. Could not touch 15.2. I'll be back here in the near future. Closing above 14.72 is bullish

0 · Reply

Neurogirl Jan. 13 at 8:23 PM

$MNMD you guys are having a speaker tomorrow at JP Morgan health conference. Anyone know about what?

1 · Reply

Marlin308 Jan. 13 at 7:58 PM

$MNMD I actually used psilocybin for alcoholism after I'd tried everything else. I couldn't last longer than 3 months, but after treatment, I got 2 years sober. And that was without certified professionals. We did the best we could though. I can only imagine what psychedelics could do with a company dedicated to therepeutic benefits. I follow mnmd specifically bc I think lsd has the most potential.

1 · Reply

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 4:01 PM EST - 4 weeks ago

MindMed Announces New Employee Inducement Grant

Dec 1, 2025, 4:01 PM EST - 6 weeks ago

MindMed Announces New Employee Inducement Grants

Nov 6, 2025, 9:46 PM EST - 2 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:01 PM EST - 2 months ago

MindMed Reports Q3 2025 Financial Results and Business Updates

Nov 5, 2025, 7:01 AM EST - 2 months ago

MindMed to Participate in Upcoming Investor Conferences

Nov 3, 2025, 7:01 AM EST - 2 months ago

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 30, 2025, 4:01 PM EDT - 2 months ago

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Oct 29, 2025, 10:14 PM EDT - 2 months ago

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Oct 29, 2025, 4:01 PM EDT - 2 months ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Oct 14, 2025, 12:28 PM EDT - 3 months ago

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Oct 13, 2025, 2:54 PM EDT - 3 months ago

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Sep 19, 2025, 7:00 AM EDT - 4 months ago

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Sep 4, 2025, 11:05 AM EDT - 4 months ago

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

Aug 28, 2025, 7:00 AM EDT - 4 months ago

MindMed to Participate in September Investor Conferences

Jul 31, 2025, 9:48 PM EDT - 5 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:01 PM EDT - 5 months ago

MindMed Reports Q2 2025 Financial Results and Business Updates

Jul 24, 2025, 7:00 AM EDT - 6 months ago

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

May 28, 2025, 7:00 AM EDT - 8 months ago

MindMed to Participate in June Investor Conferences

May 27, 2025, 7:00 AM EDT - 8 months ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 13, 2025, 7:00 AM EDT - 8 months ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 8, 2025, 9:55 AM EDT - 8 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 8 months ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

Apr 24, 2025, 7:00 AM EDT - 9 months ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 15, 2025, 7:00 AM EDT - 9 months ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Mar 17, 2025, 7:00 AM EDT - 10 months ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 6, 2025, 12:10 PM EST - 11 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 7:00 AM EST - 11 months ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 4, 2025, 7:00 AM EST - 11 months ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

Feb 20, 2025, 7:00 AM EST - 11 months ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Dec 19, 2024, 7:00 AM EST - 1 year ago

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 16, 2024, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Dec 11, 2024, 7:00 AM EST - 1 year ago

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Dec 5, 2024, 7:00 AM EST - 1 year ago

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Dec 3, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

Nov 18, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Nov 10, 2024, 9:55 AM EST - 1 year ago

Mind Medicine: No News = Good News

Nov 7, 2024, 8:06 PM EST - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 1 year ago

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Nov 4, 2024, 4:04 PM EST - 1 year ago

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

Oct 24, 2024, 7:00 AM EDT - 1 year ago

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Aug 15, 2024, 12:30 PM EDT - 1 year ago

Psychedelic Stocks: Focus On Their Cash

CMPS

Aug 13, 2024, 11:21 AM EDT - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:44 AM EDT - 1 year ago

MindMed readying Phase III trials for LSD therapy to treat anxiety

Aug 13, 2024, 7:01 AM EDT - 1 year ago

Pacific Defense Announces US Army CMFF Program Team

MRNS

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

Aug 12, 2024, 12:47 PM EDT - 1 year ago

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

ATAI CMPS

a_rational_investor Jan. 14 at 2:59 PM

$MNMD can’t wait for tomorrows ticker change. I know it doesn’t matter much but it’s almost as if we’re starting a new era and gearing up for a great 2026 with some great phase threes

1 · Reply

Rocketzz Jan. 14 at 3:37 AM

$MNMD phase 3 results are going to drop the morning after Goral’s mom kicks him off her cell phone plan and changes the WiFi password. Kids gonna get rekt

1 · Reply

CANADX Jan. 14 at 12:20 AM

$MNMD I just keep holding. It’s been 5 years and all I know is mushrooms are good and $NUMI.X my other mushroom play stopped trading a long time ago.

1 · Reply

lindakooy Jan. 13 at 10:31 PM

$MNMD interesting company.

1 · Reply

Rocketzz Jan. 13 at 9:45 PM

$MNMD larger market cap than $ATAI

2 · Reply

Rocketzz Jan. 13 at 9:34 PM

$MNMD

0 · Reply

flamingojack Jan. 13 at 9:21 PM

$MNMD

0 · Reply

Alien1980 Jan. 13 at 8:57 PM

$MNMD was all buys above 14.72. Another quick scalp back to 15.1. Could not touch 15.2. I'll be back here in the near future. Closing above 14.72 is bullish

0 · Reply

Neurogirl Jan. 13 at 8:23 PM

$MNMD you guys are having a speaker tomorrow at JP Morgan health conference. Anyone know about what?

1 · Reply

Marlin308 Jan. 13 at 7:58 PM

1 · Reply

smile696 Jan. 13 at 7:44 PM

$MNMD Well, we’re up 9% so somebody doesn’t think it’s a bad idea for whatever reason

0 · Reply

a_rational_investor Jan. 13 at 7:25 PM

$MNMD what a day!

0 · Reply

blipper Jan. 13 at 7:21 PM

$MNMD goodbye old friend…

0 · Reply

BullsVSBearsVSYoMomma Jan. 13 at 7:21 PM

$MNMD

0 · Reply

goral17 Jan. 13 at 4:04 PM

$MNMD The chart says it all... Watch out! 🙄

1 · Reply

goral17 Jan. 13 at 3:59 PM

$MNMD The road to delisting has been paved. Reverse splits... Multiple in fact, and now the name/ticker change. Just a matter of time now! Wow. I knew it! It's good to be right! Investors that lost huge percentages? Get ready, the whole thing will be vaporized. Just zoom out on the ten yr chart and remember the hype around psychedelics a few years ago. Giant scam 🤷🏾

2 · Reply

UncleJudd Jan. 13 at 3:45 PM

$ATAI $CMPS $MNMD New York Times article today https://www.nytimes.com/2026/01/13/health/shrooms-lead-the-pack-in-psychedelic-medicine-but-rollout-is-bumpy.html

2 · Reply

goral17 Jan. 13 at 3:43 PM

$MNMD This is a ticking time bomb. Short every pop from here on out. The expense to short will be even higher, astronomical... And for good reason. The name/ticker change is a wall street scam tactic.

1 · Reply

Rocketzz Jan. 13 at 3:42 PM

$MNMD

0 · Reply

BobbyCucumber Jan. 13 at 3:17 PM

$MNMD

0 · Reply

a_rational_investor Jan. 13 at 2:12 PM

$MNMD wasn’t the ticker change supposed to be today?

1 · Reply

Wingerode Jan. 13 at 1:36 PM

$MNMD $DFTX The name change is an indication the results are not heading towards medicinal but therapeutic. This aligns with research on efficacy requiring therapy guidance and limited duration in conjunction with the drug use. Thinking Bearish first then bullish again later

1 · Reply

Market Cap	1.37B
Revenue (ttm)	0.00
Net Income (ttm)	-108.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.31

Volume	3,222,100
Avg Vol	2,014,878
Day's Range	N/A - N/A
Shares Out	98.51M
Stochastic %K	83%
Beta	2.57
Analysts	Strong Sell
Price Target	$28.58